Literature DB >> 7673991

Speech and language disorders in patients with high grade glioma and its influence on prognosis.

R Thomas1, A M O'Connor, S Ashley.   

Abstract

One hundred and sixteen patients with high grade glioma were entered into a prospective phase two study and treated with accelerated radiotherapy from 1988 to 1993. In this cohort of patients we analysed speech deficit as a subdivision of global functional status in terms of incidence, category and prognosis for survival. Forty three patients (37%) had a speech deficit at presentation. Eighty percent of these had a component of expressive dysphasia, associated with considerable degree of awareness and distress. The overall median survival was 9.5 months. On univariate analysis, median survival in patients with speech difficulties (6 months) was worse than patients with normal speech (10.5 months) (log rang p = 0.005). Multivariate analysis established independent significance from age, Karnofsky Performance Status (KPS), gender, histological grade, extent of surgery and seizures. This paper highlights the importance of assessing individual categories of functional disability which in patients with high grade glioma include mobility, cognitive function and communication. Each of these factors may seriously affect an individual's activities of daily living, hence quality of life and separate analysis has a number of clinical implications. Firstly, with over a third of patients suffering speech difficulties, adequate speech therapy facilities should be freely available to score the degree of deficit, devise coping strategies and institute communication therapy. Secondly, an understanding of prognostic factors aids the critical analysis of phase two studies and the design and stratification of future prospective trials which should include an analysis of speech deficit. Thirdly, separating individual patients into good and bad prognostic groups can assist strategic management decisions.

Entities:  

Mesh:

Year:  1995        PMID: 7673991     DOI: 10.1007/bf01059960

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  19 in total

1.  ADL status in stroke: relative merits of three standard indexes.

Authors:  G E Gresham; T F Phillips; M L Labi
Journal:  Arch Phys Med Rehabil       Date:  1980-08       Impact factor: 3.966

2.  Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma.

Authors:  M Deutsch; S B Green; T A Strike; P C Burger; J T Robertson; R G Selker; W R Shapiro; J Mealey; J Ransohoff; P Paoletti
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-06       Impact factor: 7.038

3.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.

Authors:  W J Curran; C B Scott; J Horton; J S Nelson; A S Weinstein; A J Fischbach; C H Chang; M Rotman; S O Asbell; R E Krisch
Journal:  J Natl Cancer Inst       Date:  1993-05-05       Impact factor: 13.506

4.  Stroke rehabilitation: analysis of repeated Barthel index measures.

Authors:  C V Granger; L S Dewis; N C Peters; C C Sherwood; J E Barrett
Journal:  Arch Phys Med Rehabil       Date:  1979-01       Impact factor: 3.966

5.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.

Authors:  M D Walker; S B Green; D P Byar; E Alexander; U Batzdorf; W H Brooks; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; G Owens; J Ransohoff; J T Robertson; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  N Engl J Med       Date:  1980-12-04       Impact factor: 91.245

6.  Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma.

Authors:  S B Green; D P Byar; M D Walker; D A Pistenmaa; E Alexander; U Batzdorf; W H Brooks; W E Hunt; J Mealey; G L Odom; P Paoletti; J Ransohoff; J T Robertson; R G Selker; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  Cancer Treat Rep       Date:  1983-02

7.  Evaluation of CCNU, VM-26 plus CCNU, and procarbazine in supratentorial brain gliomas. Final evaluation of a randomized study. European Organization for Research on Treatment of Cancer (EORTC) Brain Tumor Group.

Authors: 
Journal:  J Neurosurg       Date:  1981-07       Impact factor: 5.115

8.  Influence of age, sex, literacy and pathologic lesion on incidence, severity and type of aphasia.

Authors:  G Miceli; C Caltagirone; G Gainotti; C Masullo; M C Silveri; G Villa
Journal:  Acta Neurol Scand       Date:  1981-11       Impact factor: 3.209

9.  Improving the acceptability of high-dose radiotherapy by reducing the duration of treatment: accelerated radiotherapy in high-grade glioma.

Authors:  M Brada; G Thomas; S Elyan; N James; F Hines; S Ashley; H Marsh; B A Bell; S Stenning
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  3 in total

1.  'Moderate global aphasia': A generalized decline of language processing caused by glioma surgery but not stroke.

Authors:  Andrey Zyryanov; Ekaterina Stupina; Elizaveta Gordeyeva; Olga Buivolova; Evdokiia Novozhilova; Yulia Akinina; Oleg Bronov; Natalia Gronskaya; Galina Gunenko; Ekaterina Iskra; Elena Ivanova; Anton Kalinovskiy; Evgenii Kliuev; Dmitry Kopachev; Elena Kremneva; Oksana Kryuchkova; Igor Medyanik; Nikita Pedyash; Viktoria Pozdniakova; Igor Pronin; Kristina Rainich; Andrey Reutov; Anastasia Samoukina; Anastasia Shlyakhova; Andrey Sitnikov; Olga Soloukhina; Konstantin Yashin; Valeriya Zelenkova; Andrey Zuev; Maria V Ivanova; Olga Dragoy
Journal:  Brain Lang       Date:  2021-12-06       Impact factor: 2.381

2.  Mass Effect Deformation Heterogeneity (MEDH) on Gadolinium-contrast T1-weighted MRI is associated with decreased survival in patients with right cerebral hemisphere Glioblastoma: A feasibility study.

Authors:  Prateek Prasanna; Jhimli Mitra; Niha Beig; Ameya Nayate; Jay Patel; Soumya Ghose; Rajat Thawani; Sasan Partovi; Anant Madabhushi; Pallavi Tiwari
Journal:  Sci Rep       Date:  2019-02-04       Impact factor: 4.379

3.  Association between lesion location and language function in adult glioma using voxel-based lesion-symptom mapping.

Authors:  Pia Banerjee; Kevin Leu; Robert J Harris; Timothy F Cloughesy; Albert Lai; Phioanh L Nghiemphu; Whitney B Pope; Susan Y Bookheimer; Benjamin M Ellingson
Journal:  Neuroimage Clin       Date:  2015-10-23       Impact factor: 4.881

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.